vTv Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
05/05/2025 12:51
vTv Therapeutics Inc VTVT.OQ VTVT.O is expected to report resultson May 7 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for vTv Therapeutics Inc is for a loss of 81 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for vTv Therapeutics Inc is $35.50, above its last closing price of $22.46. This summary was machine generated May 5 at 11:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)